JP2007509116A5 - - Google Patents

Download PDF

Info

Publication number
JP2007509116A5
JP2007509116A5 JP2006536167A JP2006536167A JP2007509116A5 JP 2007509116 A5 JP2007509116 A5 JP 2007509116A5 JP 2006536167 A JP2006536167 A JP 2006536167A JP 2006536167 A JP2006536167 A JP 2006536167A JP 2007509116 A5 JP2007509116 A5 JP 2007509116A5
Authority
JP
Japan
Prior art keywords
methyl
nitro
phenylamino
trifluoromethyl
ylamino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006536167A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007509116A (ja
Filing date
Publication date
Priority claimed from GBGB0324551.1A external-priority patent/GB0324551D0/en
Application filed filed Critical
Publication of JP2007509116A publication Critical patent/JP2007509116A/ja
Publication of JP2007509116A5 publication Critical patent/JP2007509116A5/ja
Pending legal-status Critical Current

Links

JP2006536167A 2003-10-21 2004-10-21 アンドロゲン受容体モジュレーター Pending JP2007509116A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0324551.1A GB0324551D0 (en) 2003-10-21 2003-10-21 Novel compounds
PCT/GB2004/004464 WO2005042464A1 (en) 2003-10-21 2004-10-21 Androgen receptor modulators

Publications (2)

Publication Number Publication Date
JP2007509116A JP2007509116A (ja) 2007-04-12
JP2007509116A5 true JP2007509116A5 (enExample) 2007-12-06

Family

ID=29595536

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006536167A Pending JP2007509116A (ja) 2003-10-21 2004-10-21 アンドロゲン受容体モジュレーター

Country Status (7)

Country Link
US (1) US20080058383A1 (enExample)
EP (1) EP1685090A1 (enExample)
JP (1) JP2007509116A (enExample)
AU (1) AU2004285744A1 (enExample)
CA (1) CA2543345A1 (enExample)
GB (1) GB0324551D0 (enExample)
WO (1) WO2005042464A1 (enExample)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3997255B2 (ja) 2004-02-13 2007-10-24 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー アンドロゲンレセプターモジュレーター
BRPI0509759A (pt) 2004-04-13 2007-10-16 Warner Lambert Co moduladores de androgênio
CA2562672C (en) 2004-04-22 2009-09-29 Warner-Lambert Company Llc 4-cyano-phenoxy derivatives as androgen modulators
CA2565544A1 (en) * 2004-05-11 2005-11-17 Pfizer Products Inc. Benzonitrile derivatives to treat musculoskeletal frailty
MXPA06015169A (es) 2004-07-08 2007-08-21 Warner Lambert Co Moduladores de androgenos.
WO2006044707A1 (en) * 2004-10-13 2006-04-27 Smithkline Beecham Corporation Chemical compounds
RU2007130558A (ru) 2005-01-10 2009-02-20 Акэдиа Фармасьютикалз Инк. (Us) Производные аминофенола в качестве селективных модуляторов андрогеновых рецепторов
TW200724139A (en) 2005-05-05 2007-07-01 Warner Lambert Co Androgen modulators
EP2051935B1 (en) 2006-07-26 2016-09-07 STMicroelectronics Srl Use of nitroaniline derivatives for the production of nitric oxide
US8067448B2 (en) 2008-02-22 2011-11-29 Radius Health, Inc. Selective androgen receptor modulators
US8268872B2 (en) 2008-02-22 2012-09-18 Radius Health, Inc. Selective androgen receptor modulators
WO2010000066A1 (en) 2008-07-02 2010-01-07 British Columbia Cancer Agency Branch Diglycidic ether derivative therapeutics and methods for their use
EP2367794B1 (en) * 2008-11-24 2013-01-09 Basf Se Curable composition comprising a thermolatent base
WO2010067987A2 (ko) * 2008-12-10 2010-06-17 동화약품주식회사 신규한 2, 6-위치에 치환된 3-니트로피리딘 유도체, 그의 제조방법 및 이를 포함하는 약학 조성물
US9962368B2 (en) 2009-01-09 2018-05-08 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
US9162980B2 (en) 2009-01-09 2015-10-20 Board Of Regents Of The University Of Texas System Anti-depression compounds
US8362277B2 (en) 2009-01-09 2013-01-29 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
WO2010081115A1 (en) * 2009-01-09 2010-07-15 University Of Texas Southwestern Medical Center Pro-neurogenic compounds
TWI625121B (zh) 2009-07-13 2018-06-01 基利科學股份有限公司 調節細胞凋亡信號之激酶的抑制劑
FR2954315B1 (fr) 2009-12-23 2012-02-24 Galderma Res & Dev Nouveaux derives phenoliques, et leur utilisation pharmaceutique ou cosmetique
FR2954316B1 (fr) * 2009-12-23 2014-01-03 Galderma Res & Dev Nouveaux derives phenoliques, et leur utilisation pharmaceutique ou cosmetique
FR2954317B1 (fr) 2009-12-23 2012-01-27 Galderma Res & Dev Nouveaux derives phenoliques, et leur utilisation pharmaceutique ou cosmetique
EP2521707B1 (en) 2010-01-06 2017-06-14 British Columbia Cancer Agency Branch Bisphenol derivatives and their use as androgen receptor activity modulators
MX338831B (es) 2010-02-04 2016-05-03 Radius Health Inc Moduladores selectivos de receptores de androgenos.
SI2568806T1 (sl) 2010-05-12 2016-09-30 Radius Health, Inc. Režimi zdravljenja
US8642632B2 (en) 2010-07-02 2014-02-04 Radius Health, Inc. Selective androgen receptor modulators
AU2011274369A1 (en) * 2010-07-02 2012-12-06 Ventana Medical Systems, Inc. Hapten conjugates for target detection
CN103415289B (zh) 2010-07-07 2017-04-12 得克萨斯州大学系统董事会 前神经原性化合物
AU2011312490B2 (en) 2010-09-28 2015-06-25 Radius Pharmaceuticals, Inc. Selective androgen receptor modulators
US9365510B2 (en) 2012-04-16 2016-06-14 British Columbia Cancer Agency Branch Aziridine bisphenol ethers and related compounds and methods for their use
CA2882826A1 (en) 2012-08-24 2014-02-27 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
CA2922192A1 (en) 2013-09-09 2015-03-12 British Columbia Cancer Agency Branch Halogenated compounds for cancer imaging and treatment and methods for their use
EP3068388A4 (en) 2013-11-11 2017-04-12 Board of Regents of the University of Texas System Neuroprotective compounds and use thereof
WO2015070237A1 (en) 2013-11-11 2015-05-14 Board Of Regents Of The University Of Texas System Neuroprotective chemicals and methods for identifying and using same
PT3122426T (pt) 2014-03-28 2023-02-28 Univ Duke Tratamento de cancro da mama utilizando moduladores seletivos do recetor de estrogénio
US9421264B2 (en) 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
PT3237404T (pt) 2014-12-23 2021-01-19 Gilead Sciences Inc Processos de preparação de inibidores ask1
ES2907708T3 (es) 2015-01-13 2022-04-26 British Columbia Cancer Agency Branch Compuestos heterocíclicos para obtención de imágenes y tratamiento del cáncer y métodos para su uso
WO2016141458A1 (en) 2015-03-12 2016-09-15 British Columbia Cancer Agency Branch Bisphenol ether derivatives and methods for using the same
EP3288383A4 (en) 2015-04-29 2019-01-23 Radius Pharmaceuticals, Inc. METHOD FOR THE TREATMENT OF CANCER
US20170298033A1 (en) 2016-04-15 2017-10-19 The University Of British Columbia Bisphenol derivatives and their use as androgen receptor activity modulators
HRP20220619T1 (hr) 2016-06-22 2023-02-03 Ellipses Pharma Ltd Postupci za liječenje ar+ raka dojke
ES2981967T3 (es) 2017-01-05 2024-10-14 Radius Pharmaceuticals Inc Formas polimórficas de RAD1901-2HCl
TW201900604A (zh) 2017-05-18 2019-01-01 印度商Ｐｉ工業公司 新穎的脒化合物
US11485713B2 (en) 2018-05-25 2022-11-01 Essa Pharma, Inc. Androgen receptor modulators and methods for their use
JP7473486B2 (ja) 2018-07-04 2024-04-23 ラジウス ファーマシューティカルズ，インコーポレイテッド Ｒａｄ１９０１－２ｈｃｌの多形形態
WO2020081999A1 (en) 2018-10-18 2020-04-23 Essa Pharma, Inc. Androgen receptor modulators and methods for their use
JOP20210218A1 (ar) 2019-02-12 2023-01-30 Radius Pharmaceuticals Inc عمليات ومركبات
US12109179B2 (en) 2019-03-28 2024-10-08 Essa Pharma Inc. Pharmaceutical compositions and combinations comprising inhibitors of the androgen receptor and uses thereof
CN115916170A (zh) 2020-04-17 2023-04-04 埃萨制药股份有限公司 固体形式的n-末端结构域雄激素受体抑制剂及其用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3970423A (en) * 1971-10-04 1976-07-20 Clairol Incorporated Oxidative hair dye compositions
CA1012553A (en) 1972-06-23 1977-06-21 Hirotoshi Nakanishi Process for the production of aromatic diamines
JPS4920129A (enExample) * 1972-06-23 1974-02-22
US4723986A (en) 1986-05-19 1988-02-09 Stauffer Chemical Company Herbicidal oxazolidines and methods of use
JP2701090B2 (ja) * 1990-11-30 1998-01-21 和光純薬工業株式会社 被酸化性呈色試薬
JPH0580375A (ja) * 1991-09-20 1993-04-02 Japan Synthetic Rubber Co Ltd 有機非線形光学素子
JPH0920129A (ja) * 1995-07-05 1997-01-21 Suzuki Motor Corp 車両用暖房装置
DE19612506A1 (de) * 1996-03-29 1997-10-02 Wella Ag Oxidationshaarfärbemittel mit einem Gehalt an 2,5-Diaminobenzonitrilen sowie neue 2,5-Diaminobenzonitrile
JP2001526265A (ja) * 1997-12-22 2001-12-18 ファルマシア・アンド・アップジョン・カンパニー 抗ウイルス剤としての４−ヒドロキシキノリン−３−カルボキサミドおよびヒドラジド
US20020193389A1 (en) * 1998-11-20 2002-12-19 Rifat Pamukeu Method of inhibiting neoplastic cells with imidazoquinazoline derivatives
US6472415B1 (en) * 1998-12-18 2002-10-29 Biophysica, Inc. Androgen receptor suppressors in the therapy and diagnosis of prostate cancer, alopecia and other hyper-androgenic syndromes
GB0004887D0 (en) * 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
AU2001285230C1 (en) * 2000-08-24 2008-03-13 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
CN100506801C (zh) * 2000-09-06 2009-07-01 诺华疫苗和诊断公司 糖元合成酶激酶3的抑制剂
MXPA04005510A (es) * 2001-12-07 2006-02-24 Vertex Pharma Compuestos basados en pirimidina utiles como inhibidores de gsk-3.
DE10163251A1 (de) * 2001-12-21 2003-07-03 Henkel Kgaa Neue Entwicklerkomponenten

Similar Documents

Publication Publication Date Title
JP2007509116A5 (enExample)
EP2516398B1 (fr) Derives phenoliques, et leur utilisation pharmaceutique ou cosmetique
US5776951A (en) Anti-atherosclerotic diaryl compounds
RU2632875C2 (ru) Способы получения (s)-1-(3-этокси-4-метоксифенил)-2- метансульфонилэтиламина
CN1310899C (zh) 具有杀虫、杀菌活性的苯并吡喃酮类化合物及制备与应用
JP2015526487A5 (enExample)
CZ20032727A3 (cs) Derivát karboxylové kyseliny a jeho sůl
JP2010090128A (ja) 結晶質の化合物ビス［（ｅ）−７−［４−（４−フルオロフェニル）−６−イソプロピル−２−［メチル（メチルスルホニル）アミノ］ピリミジン−５−イル］（３ｒ，５ｓ）−３，５−ジヒドロキシ−６−ヘプテン酸］カルシウム塩
EP1731506A1 (en) 5-hydroxyindole-3-carboxylates derivatives and their use
AU2013277423B2 (en) Compounds with (1E, 6E)-1,7-bis-(3,4-dimethoxyphenyl)-4,4-disstituted-hepa-1,6-diene-3,5-dione structural scaffold, their biological activity, and uses thereof
JP7443414B2 (ja) アンドロゲン受容体のｎ末端ドメインの阻害剤
CS242881B2 (en) Method of 1,4-dihydropyridine's new derivatives production
SK13752002A3 (sk) Difenyléterové zlúčeniny užitočné pri liečení
CZ334998A3 (cs) Substituované benzylaminy a farmaceutický prostředek
JPWO2020132014A5 (enExample)
CN1192728A (zh) 苯基烷烃酰胺衍生物及农业或园艺杀菌剂
SK285037B6 (sk) Spôsob výroby 2-aryl-3-aryl-5-halogénpyridínov
CN1533378A (zh) 制备喹唑啉的方法
CN107848968B (zh) 从乙醛酸制备内酰胺的方法
CN1317265C (zh) 氰基丙烯酸酯衍生物及制备方法和生物活性
CN1633411A (zh) 用于调节细胞增生的化合物
TWI884201B (zh) 用於製備3-溴-1-(3-氯吡啶-2-基)-1h-吡唑-5-羧酸乙酯的方法
AU2010303243A1 (en) Processes for the preparation of 2-(1-phenylethyl) isoindolin-1-one compounds
JP5712226B2 (ja) 新規なフェノール誘導体、及び医薬として又は化粧品としてのその使用
CN1166650C (zh) 1,2,3-噻二唑类化合物及其制备方法和生物活性